Buchumschlag

A Precision Mixture Risk Model to Identify Adverse Drug Events in Subpopulations Using a Case‐Crossover Design

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Yi Shi, Michael T. Eadon, Yao Chen, Anna Sun, Yuedi Yang, Chienwei Chiang, Macarius Donneyong, Jing Su, Pengyue Zhang
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Statistics in Medicine
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

A Dose‐Aware Model for Revealing Dose‐Risk Relationship of Drug–Drug Interaction
von: Yi Shi, et al.
Veröffentlicht: (2025)

Identifying Adverse Events Associated With High‐Risk Opioid Administration Using the Emergency Department Trigger Tool
von: Richard T. Griffey, et al.
Veröffentlicht: (2026)

Potential Drug Dose‐Specific Adverse Three‐Drug Combinations: A US Insurance Claims Data‐Based Study
von: Y. Shi, et al.
Veröffentlicht: (2025)

Prevalence of potentially inappropriately prescribed medications among older adults receiving peritoneal dialysis
von: Armando Silva Almodovar, et al.
Veröffentlicht: (2025)

Evaluation of Anticancer Therapy‐Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset
von: Wei Wang, et al.
Veröffentlicht: (2026)

Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System
von: Shaimaa Elshafie, et al.
Veröffentlicht: (2024)

Modifiable Geriatric Risk Factors Identified by CGA Predict Adverse Outcomes in Frail Vietnamese Older Adults: A 12‐Month Longitudinal Study
von: Huong Thi Mai Nguyen, et al.
Veröffentlicht: (2026)

Improve the Precision of Area Under the Curve Estimation for Recurrent Events Through Covariate Adjustment
von: Jiren Sun, et al.
Veröffentlicht: (2025)

Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer
von: Natansh D. Modi, et al.
Veröffentlicht: (2025)

Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients During Treatment With Bosutinib
von: E. Agostani, et al.
Veröffentlicht: (2025)

Remarkable Antitumor Effects and Serious Multiple Immune‐Related Adverse Events in Malignant Pleural Mesothelioma: Two Case Reports
von: Koharu Harada, et al.
Veröffentlicht: (2025)

Hypercalcemia as an Immune‐Related Adverse Event in a Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report
von: Sam Plessers, et al.
Veröffentlicht: (2025)

A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine
von: Yuan Li, et al.
Veröffentlicht: (2025)

Neoplasm Adverse Events Associated With Anti‐Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study
von: Wen Lyu, et al.
Veröffentlicht: (2026)

Total Testosterone Measured by Liquid Chromatograph‐Tandem Mass Spectrometry Refines Diagnosis of Biochemical Hyperandrogenism and Better Identifies Subgroup at Genuine Risk of Adverse Fertility Outcomes in Women With Polycystic Ovary Syndrome
von: Jian Li, et al.
Veröffentlicht: (2026)

Identifying Causal Inflammatory Factors With Gene Mediators and Potential Drugs for Bronchiectasis
von: Wanzhe Liao, et al.
Veröffentlicht: (2025)

A Real‐World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System ( FAERS ) Database
von: Yajing Xu, et al.
Veröffentlicht: (2025)

Correlation Between Treatment‐Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma
von: Ting Zhang, et al.
Veröffentlicht: (2025)

Impact of Thiazides and Fluoropyrimidines Interaction on Myelotoxicity and Other Adverse Events in Real‐World Practice: A Retrospective Cohort Study
von: Gerard Ronda‐Roca, et al.
Veröffentlicht: (2026)

A Nonparametric Bayesian Local–Global Model for Enhanced Adverse Event Signal Detection in Spontaneous Reporting System Data
von: Xin‐Wei Huang, et al.
Veröffentlicht: (2026)

Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled Trials
von: Jingyan Fu, et al.
Veröffentlicht: (2025)

Hepatic‐Differentiated Subpopulation in Clear Cell Renal Cell Carcinoma: A Multi‐Omics Analysis of Tumors With Lymphovascular Invasion
von: Shugo Yajima, et al.
Veröffentlicht: (2026)

Risk Factors and Prediction Model for Early‐Onset Immune‐Related Adverse Events in Pan‐Cancer Patients Undergoing Anti‐ PD ‐(L)1 Therapy: A Retrospective Study in a Tertiary‐Level Hospital
von: Panpan Jiao, et al.
Veröffentlicht: (2026)

Endocrinologist‐Led Management of Endocrine Immune‐Related Adverse Events: Real‐World Evidence Supporting the Japan Endocrine Society Guidelines
von: Kota Nishihama, et al.
Veröffentlicht: (2026)

Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study
von: Amanda Nizam, et al.
Veröffentlicht: (2025)

Therapeutic failure reported with HIV long‐acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024
von: Kenneth L. McCall, et al.
Veröffentlicht: (2024)

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints
von: Xinran Huang, et al.
Veröffentlicht: (2024)

Joint Frailty Mixture Cure Model for Recurrent Event Data With Dependent Censoring: An MCEM Approach
von: Nasrin Sultana, et al.
Veröffentlicht: (2026)

Significantly Delayed Development of Polyarthritis with Active Tenosynovitis after Possible Temporary Neutropenic Immune-Related Adverse Events Caused by Atezolizumab Treatment: A Novel Case Report
von: Yoshitaka Saito, et al.
Veröffentlicht: (2024)

A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database
von: Boyi Liu, et al.
Veröffentlicht: (2026)

Immune‐Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis
von: Pooja Gokhale, et al.
Veröffentlicht: (2026)

A Transcriptome‐Wide Association Study Identifies Candidate Susceptibility Loci and Genes for Lung Cancer Risk
von: Tianying Zhao, et al.
Veröffentlicht: (2025)

Advancing Precision Medicine: The Role of Genetic Testing and Sequencing Technologies in Identifying Biological Markers for Rare Cancers
von: Joviana Farhat, et al.
Veröffentlicht: (2025)

Exploring the Protein–Metabolite Interplay to Discover Novel Drug Targets for Alzheimer's Disease
von: Kang‐Fu Yin, et al.
Veröffentlicht: (2025)

Risk Factors for Financial Toxicity in Patients With Pancreatic Cancer
von: Jing Wang, et al.
Veröffentlicht: (2025)

Non‐Parametric Estimation for Semi‐Competing Risks Data With Event Misascertainment
von: Ruiqian Wu, et al.
Veröffentlicht: (2025)

Efficient Risk Assessment of Time‐to‐Event Targets With Adaptive Information Transfer
von: Jie Ding, et al.
Veröffentlicht: (2024)

Running Shoe Recommendations Based on Gait Analysis Improve Perceptions of Comfort, Performance and Injury Risk: A Single‐Blind Randomised Crossover Trial
von: Andrew Fife, et al.
Veröffentlicht: (2025)

Development and Validation of a Nomogram Incorporating Preoperative N‐Terminal Pro‐Brain Natriuretic Peptide to Predict Major Adverse Cardiovascular Events in Renal Transplant Recipients
von: Guobin Wu, et al.
Veröffentlicht: (2026)

Jointly Modeling Time‐To‐Event and Longitudinal Data With Individual‐Specific Change Points: A Case Study in Modeling Tumor Burden
von: Ethan M. Alt, et al.
Veröffentlicht: (2025)